Accessibility Menu
 
Stoke Therapeutics logo

Stoke Therapeutics

(NASDAQ) STOK

Current Price$35.15
Market Cap$2.12B
Since IPO (2019)+40%
5 Year+9%
1 Year+374%
1 Month+8%

Stoke Therapeutics Financials at a Glance

Market Cap

$2.12B

Revenue (TTM)

$184.42M

Net Income (TTM)

$6.88M

EPS (TTM)

$-0.15

P/E Ratio

-241.48

Dividend

$0.00

Beta (Volatility)

1.37 (Average)

Price

$35.15

Volume

5,514

Open

$36.16

Previous Close

$35.86

Daily Range

$35.01 - $36.33

52-Week Range

$7.31 - $40.22

STOK: Motley Fool Moneyball Superscore

75

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Stoke Therapeutics

Industry

Biotechnology

Employees

170

CEO

Ian Frederick Smith, CPA

Headquarters

Bedford, MA 01730, US

STOK Financials

Key Financial Metrics (TTM)

Gross Margin

99%

Operating Margin

-11%

Net Income Margin

-4%

Return on Equity

-2%

Return on Capital

-6%

Return on Assets

-2%

Earnings Yield

-0.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.12B

Shares Outstanding

59.15M

Volume

5.51K

Short Interest

0.00%

Avg. Volume

770.10K

Financials (TTM)

Gross Profit

$184.42M

Operating Income

$20.59M

EBITDA

$18.82M

Operating Cash Flow

$45.59M

Capital Expenditure

$670.00K

Free Cash Flow

$44.91M

Cash & ST Invst.

$284.67M

Total Debt

$0.00

Stoke Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.40M

-93.8%

Gross Profit

$347.00K

-98.5%

Gross Margin

24.75%

N/A

Market Cap

$2.12B

N/A

Market Cap/Employee

$16.57M

N/A

Employees

128

N/A

Net Income

$57.93M

-452.7%

EBITDA

$60.38M

-360.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$284.67M

+32.7%

Accounts Receivable

$7.91M

+1029.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.65%

N/A

Return on Invested Capital

-5.71%

N/A

Free Cash Flow

$30.69M

-32.1%

Operating Cash Flow

$30.45M

-31.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZYMEZymeworks Inc.
$27.13+0.56%
BCRXBioCryst Pharmaceuticals, Inc.
$9.55-1.19%
PHVSPharvaris N.V.
$28.46-0.77%
NTLAIntellia Therapeutics, Inc.
$14.53-1.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.15+0.14%
SNAPSnap
$5.97+0.07%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.83-0.01%
RGTIRigetti Computing
$18.84+0.12%

Questions About STOK

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.